- Home
- OMCC vs ACHL Comparison
OMCC vs ACHL Comparison
Compare OMCC & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCC
- ACHL
- Stock Information
- Founded
- OMCC 1985
- ACHL 2016
- Country
- OMCC United States
- ACHL United Kingdom
- Employees
- OMCC N/A
- ACHL N/A
- Industry
- OMCC
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OMCC
- ACHL Health Care
- Exchange
- OMCC NYSE
- ACHL Nasdaq
- Market Cap
- OMCC 43.4M
- ACHL 40.4M
- IPO Year
- OMCC N/A
- ACHL 2021
- Fundamental
- Price
- OMCC $6.09
- ACHL $1.07
- Analyst Decision
- OMCC
- ACHL Hold
- Analyst Count
- OMCC 0
- ACHL 3
- Target Price
- OMCC N/A
- ACHL $2.83
- AVG Volume (30 Days)
- OMCC 16.2K
- ACHL 141.2K
- Earning Date
- OMCC 11-13-2024
- ACHL 11-14-2024
- Dividend Yield
- OMCC N/A
- ACHL N/A
- EPS Growth
- OMCC N/A
- ACHL N/A
- EPS
- OMCC N/A
- ACHL N/A
- Revenue
- OMCC $22,185,000.00
- ACHL N/A
- Revenue This Year
- OMCC N/A
- ACHL N/A
- Revenue Next Year
- OMCC N/A
- ACHL N/A
- P/E Ratio
- OMCC N/A
- ACHL N/A
- Revenue Growth
- OMCC N/A
- ACHL N/A
- 52 Week Low
- OMCC $5.29
- ACHL $0.63
- 52 Week High
- OMCC $7.55
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- OMCC N/A
- ACHL 64.24
- Support Level
- OMCC N/A
- ACHL $1.01
- Resistance Level
- OMCC N/A
- ACHL $1.12
- Average True Range (ATR)
- OMCC 0.00
- ACHL 0.04
- MACD
- OMCC 0.00
- ACHL -0.00
- Stochastic Oscillator
- OMCC 0.00
- ACHL 61.54
About OMCC OLD MARKET CAPITAL CORPORATION
Old Market Capital Corp formerly Nicholas Financial Inc is a specialized consumer finance company. It is engaged in acquiring and servicing automobile finance installment contracts for purchases of used and new automobiles and light trucks. It also originates direct consumer loans and sells consumer-finance-related products. The majority of its revenue comes from Interest and fee income.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.